Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of BPS-314d-MR-PAH-302 in pulmonary arterial hypertension
MOH_2018-07-23_003538Phase 3Completed
- Sponsor
- Lung Biotechnology PBC
- Start
- Jun 2018
- Countries
- 1
01
Overview
Phase 3, open-label trial of azouberprost in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Lung Biotechnology PBC. Primary endpoint: Long-term safety and tolerability of azouberprost. Started Jun 2018; status: completed.
02
Drugs
azouberprost
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2018-07-23_003538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-23_003538.